First Adrenaline Nasal Spray for Anaphylaxis Approved in italy,Transforming Emergency Treatment
Rome,Italy – October 13,2025 – A new era in anaphylaxis management begins today with the approval of the first adrenaline nasal spray for emergency treatment of severe allergic reactions in Italy. The innovative delivery method promises faster administration and broader accessibility compared to traditional epinephrine auto-injectors, possibly saving lives and reducing the severity of anaphylactic episodes.
This progress marks a important shift in how anaphylactic shock – a potentially fatal,systemic allergic reaction – is addressed. Currently, treatment relies heavily on epinephrine auto-injectors, requiring patients (or bystanders) to administer a precise injection.The nasal spray offers a needle-free option, easing administration for individuals who may be anxious about injections, or whose reactions impair their ability to self-administer. Approximately 3-10% of the population experiences food allergies, and a significant percentage of those are at risk of anaphylaxis, making this advancement crucial for public health. The spray is expected to be available to patients via prescription in early 2026.
Anaphylaxis can be triggered by a wide range of allergens, including foods (peanuts, tree nuts, shellfish, milk, eggs), insect stings, medications, and latex. Symptoms escalate rapidly and can include difficulty breathing, swelling of the throat and tongue, dizziness, and a sudden drop in blood pressure. Prompt administration of epinephrine is critical to reversing these symptoms.
The approval follows accomplished clinical trials demonstrating the nasal spray’s efficacy and safety. Researchers found that the nasal spray delivered a comparable dose of epinephrine to auto-injectors, with similar absorption rates and clinical outcomes. Further details regarding the specific brand name and manufacturer will be released in the coming weeks by the Italian Medicines Agency (AIFA). This approval is anticipated to influence emergency protocols and patient education initiatives across Italy, emphasizing the importance of recognizing anaphylaxis symptoms and having readily available treatment options.
ยฉ ALL RIGHTS RESERVED